More Investment, Less Return?
Planned R&D Hike Gives Gilead Investors Pause
By Jennifer Boggs
Monday, August 4, 2008
With Gilead Sciences Inc. posting strong, even "record" sales of its HIV drug franchise for the second quarter, and launching the first of two Phase III studies of promising once-daily, HIV integrase inhibitor elvitegravir, the Foster City, Calif.-based firm's quarterly progress should have sounded like music to investors' ears. (BioWorld Financial Watch)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.